Imatinib, the first targeted therapy drug, is a first-line BCR-ABL inhibitor, which showed remarkable efficacy for most patients diagnosed with CML, with an overall 5-year survival rate of 89%4,.5 The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.